Key result
Investment and Impact Fund indicators add gastroprotective medicines to ~80% of targeted prescriptions.
The NHS Long Term Plan introduces IIF indicators to incentivize primary care networks in England to improve the detection and management of hypertension and familial hypercholesterolaemia.
Supports IIF incentives for safer prescribing; leaves open effects on hypertension and familial hypercholesterolaemia detection.
I.Improve prevention and tackling health inequalities IIF indicators in this area will support primary care networks (PCNs) to undertake a range of activity to address well known inequalities in rates of diagnosis for cardiovascular disease (CVD), delivery of Learning Disability Health Checks and the influenza vaccination to potentially high-risk cohorts.In 2021/22, there will be an indicator rewarding comprehensive of recording of ethnicity data in the GP record.This will help PCNs better understand their populations, plan and deliver services, and target interventions where necessary. CVD indicators, further detail:The NHS Long Term Plan commits to the prevention of 150,000 strokes, heart attacks and dementia cases by 2029 through the earlier detection and treatment of CVD risk factors.The IIF indicators focussing on CVD will drive relevant activity to support this ambition, with a particular focus on hypertension in 21/22: Hypertension case finding CVD is a leading cause of death and disability in England, but an estimated 30% of hypertension is undiagnosed.An estimated 3 million people have a recorded reading of high blood pressure (BP) on GP systems, but have not had appropriate follow up to confirm or rule out a hypertension diagnosis.This issue is expected to have been exacerbated during the pandemic.Indicator CVD-01 encourages PCNs to follow up more patients with an elevated BP reading (including through proactive outreach, where possible) to assess them for hypertension, typically through provision of Ambulatory or Home BP Monitoring.CVD-02 rewards PCNs for the corresponding rate of hypertension diagnoses which can be expected having undertaken appropriate follow up activity for individuals with high BP.CVD-01 complements quality outcomes framework (QOF) indicator BP002, which rewards practices for blood pressure recording.This QOF incentive means that a significant percentage of undiagnosed hypertension is known to general practice in the form of an elevated BP reading.CVD-01 rewards PCNs for adherence with NICE guidance on timely follow-up for patients to confirm or exclude a diagnosis of hypertension.Familial hypercholesterolaemia (FH) FH affects at least 150,000 people in England, but only 7% of cases were diagnosed as of 2019/20.CVD-04 will support the NHS Long Term Plan ambition to increase levels of diagnosis to 25% by 2023/24.
No takes yet. Share an insight, caveat, or question.
Wong et al. (2022) studied Primary care conditions (CVD, asthma, medication safety). Investment and Impact Fund (IIF) financial incentives was evaluated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: